Neurometrix (NASDAQ:NURO) will post its quarterly earnings results before the market opens on Thursday, July 18th. Analysts expect Neurometrix to post earnings of ($0.19) per share for the quarter.
Neurometrix (NASDAQ:NURO) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.30. The company had revenue of $3.12 million during the quarter, compared to analysts’ expectations of $3.92 million. Neurometrix had a net margin of 6.36% and a return on equity of 11.77%. On average, analysts expect Neurometrix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NURO stock opened at $0.46 on Friday. The firm has a market capitalization of $3.72 million, a P/E ratio of 3.02 and a beta of 0.50. The company has a 50-day moving average of $0.52. Neurometrix has a 52 week low of $0.36 and a 52 week high of $1.48.
A number of research analysts recently commented on NURO shares. Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. HC Wainwright reaffirmed a “buy” rating on shares of Oragenics in a research note on Friday, April 26th. Finally, ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd.
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
See Also: NASDAQ
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.